STARGLO
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- NCT04408638 ↗
- Active, not recruiting
- Hoffmann-La Roche
- Deep
We haven't built an HCP commentary report on STARGLO (obinutuzumab, glofitamab and 4 more in Diffuse Large B-cell Lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice.
The commentary discusses STARGLO as a confirmatory randomized comparison of glofitamab plus GemOx with R-GemOx in relapsed or refractory DLBCL, including its overall-survival endpoint and role for transplant-ineligible patients. Discussion covers the FDA review and whether the trial population and regional findings are applicable to patients in the United States. Speakers raise questions about regional differences, global recruitment, and the relevance of R-GemOx as a control amid changing treatment options, including CAR-T, as well as how the trial should inform treatment practice and access.
Indexed commentary on STARGLO so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 77 | |
| YouTube | 73 | |
| Podcasts | 40 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Obinutuzumab; Glofitamab; Rituxumab; Tocilizumab; Gemcitabine; Oxaliplatin
- Arms
- Glofit-GemOx · Experimental
- R-GemOx · Experimental
- Enrollment
- 270 (estimated)
- Primary outcomes
- Overall survival (OS), defined as the time from randomization to date of death from any cause
- Sponsor
- Hoffmann-La Roche
- Start
- Feb 23, 2021
- Primary completion
- Mar 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04408638 · updated Oct 2, 2026
Publications
linked from the registry- Abramson JS, Townsend W, Fox CP, Ku M, Hertzberg M, Huang HQ, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Mulvihill E, Kesavan M, Kallemeijn M, Ta R, Choeurng V, Belousov A, Relf J, Bottos A, Lundberg L, Gregory GP. Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO. Blood Adv. 2026 Aug 11;10(15):5367-5377. doi: 10.1182/bloodadvances.2026019764. PubMed 42269085
- Sam J, Leclercq-Cohen G, Gebhardt S, Surowka M, Herter S, Lechner K, Relf J, Briner S, Varol A, Appelt B, Domocos I, Nicolini V, Bez M, Bommer E, Jenni S, Schoenle A, Le Clech M, Colombetti S, Klein C, Umana P, Lundberg P, Korfi K, Bottos A, Bacac M. Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma. Blood. 2025 Oct 9;146(15):1824-1836. doi: 10.1182/blood.2025028863. PubMed 40749164
- Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024 Nov 16;404(10466):1940-1954. doi: 10.1016/S0140-6736(24)01774-4. PubMed 39550172